Targeting the Progression of Parkinson's Disease
JL George, S Mok, D Moses, S Wilkins, AI Bush, RA Cherny, DI Finkelstein
CURRENT NEUROPHARMACOLOGY | BENTHAM SCIENCE PUBL LTD | Published : 2009
By the time a patient first presents with symptoms of Parkinson's disease at the clinic, a significant proportion (50-70%) of the cells in the substantia nigra (SN) has already been destroyed. This degeneration progresses until, within a few years, most of the cells have died. Except for rare cases of familial PD, the initial trigger for cell loss is unknown. However, we do have some clues as to why the damage, once initiated, progresses unabated. It would represent a major advance in therapy to arrest cell loss at the stage when the patient first presents at the clinic. Current therapies for Parkinson's disease focus on relieving the motor symptoms of the disease, these unfortunately lose t..View full abstract
This work is funded by The National Health and Medical Research Council of Australia (NHMRC), the Australian Brain Foundation, Supported by Operational Infrastructure Support (OIS) from the Victorian State Government and Prana Biotechnology.